Virbac to distribute Prevtec microbia’s innovative Coliprotec(R) vaccine in Brazil

MONTREAL, March 28 /PRNewswire/ – Virbac, the 8(th) largest veterinarian pharmaceutical group worldwide, has concluded an
exclusive Distribution and Trademark Licence Agreement with Prevtec
microbia, a Canadian veterinarian laboratory, for the distribution of
the Coliprotec(®) vaccine in Brazil.

Coliprotec(®) is a live bacterial vaccine developed by Prevtec microbia that prevents
post-weaning diarrhea in pigs. Prevtec microbia recently secured
government approval for the distribution of its first vaccine in
Brazil, through its subsidiary, Prevtec microbia do Brasil. Virbac will
be its exclusive distributor in this emerging country, which is the
third largest producer of pork in the world. The contract with Virbac,
concluded with the help of the Trifermed Group, is Prevtec microbia’s
first international distribution agreement.

Michel Fortin, President of Prevtec microbia stated “This distribution
agreement with one of the largest pharmaceutical companies in the
world, validates the quality of the work of the research team at
Prevtec, a young Canadian agro-pharmaceutical company, which started
operations only 5 years ago”.

Thierry Gozlan, Area Director of Virbac Latin America, declared that
this agreement will strengthen Virbac’s already strong growth in
Brazil, through its subsidiary, Virbac do Brasil Ltda. Coliprotec(®) also consolidates Virbac’s recent entry into the market segment of
food-producing animal vaccines.

Coliprotec(® )is a pure culture of non virulent E. coli bacteria, administered orally to piglets in their drinking water. A
healthy alternative to antibiotics, it can be easily, safely and
economically used for prophylaxis. Unlike antibiotics, the efficacy of
Coliprotec does not reduce with use. “Coliprotec(®) perfectly fits Virbac’s thrust towards promoting responsible use of
veterinary medicines”, said Thierry Gozlan.

Brazil a world class swine producer, is expected to increase its
production and export and has undertaken to improve its production
methods. “Being a vaccine, and not an antibiotic, Coliprotec® is in
accordance with best practices in the care and feeding of
food-producing animals and can enhance production performance”, also
stated Michel Fortin.

Founded in 1968 in Carros close to Nice (France), Virbac has become the
world’s first independent laboratory dedicated exclusively to animal
health. With a turnover of EUR572.5 million in 2010, the company ranks
today as the 8(th) largest veterinarian pharmaceutical group worldwide. Its wide range of
vaccines and medicines for both companion and food-producing animals
are appreciated by veterinarians and animal owners alike. Present in
more than 100 countries, the company has more than 3150 employees.

Prevtec microbia is a Canadian company with offices in Montreal and
Saint-Hyacinthe (Quebec) as well as in Saskatoon (Saskatchewan). Its
mission is to develop new products and technologies to improve animal
health and to increase performance in the production of food animals,
such as pigs, poultry and cattle. The company has undertaken to get
regulatory approval for Coliprotec(®) and two other of its products in several countries on three continents.

SOURCE Prevtec Microbia